Novo Nordisk licenses Hengrui's experimental weekly obesity pill for up to $2.6 billion
The $300 million upfront payment buys rights to HRS-1596 outside China, Taiwan and nearby territories.
Intelligence
Earlier in Minutes · Novo Nordisk
The parties
Activity